Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06750289 · ClinicalTrials.gov registry record · Phase 3
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
A Phase 3 study of Eosinophilic Asthma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06750289: Recruiting Phase 3 study of Eosinophilic Asthma, sponsored by AstraZeneca.
NCT06750289 is a Phase 3 study of Eosinophilic Asthma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 400 participants, below the 472-participant average among 4 other Eosinophilic Asthma trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06750289, a Phase 3 study of Eosinophilic Asthma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.
Primary Outcome
To assess asthma exacerbation rate.
Conditions Studied
Interventions
- COMBINATION_PRODUCT ICS-LABA
- COMBINATION_PRODUCT benralizumab
- COMBINATION_PRODUCT Placebo for Benralizumab
Study Locations (20)
Florida
- Research Site - Cape Coral
- Research Site - Hialeah
- Research Site - Lauderdale Lakes
- Research Site - Leesburg
- Research Site - Miami
- Research Site - Miami
- Research Site - Miami
- Research Site - Orlando
- Research Site - Plantation
- Research Site - Tampa
- Research Site - Winter Park
California
- Research Site - Bakersfield
- Research Site - Inglewood
- Research Site - Modesto
- Research Site - Newport Beach
- Research Site - Pasadena
Arizona
- Research Site - Chandler
- Research Site - Sun City
- Research Site - Tucson
Colorado
- Research Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2027-11-03 |
| Phase | Phase 3 |
What NCT06750289 shows while recruiting
NCT06750289 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 472-participant average among 4 other Eosinophilic Asthma trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Eosinophilic Asthma appearing as the primary indexed condition, and to 3 interventions - of which ICS-LABA is the first listed.
NCT06750289 names 20 study sites across 4 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06750289 about?
NCT06750289 is a clinical study titled "Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment". This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.
What is the current status of trial NCT06750289?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-03-28. Estimated completion is 2027-11-03.
What conditions does trial NCT06750289 study?
This clinical trial studies the following conditions: Eosinophilic Asthma.
What interventions are being tested in trial NCT06750289?
The interventions under investigation include: ICS-LABA (COMBINATION_PRODUCT), benralizumab (COMBINATION_PRODUCT), Placebo for Benralizumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06750289?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06750289 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
COMPLETED · Phase 3
-
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
RECRUITING · Phase 2
-
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI